CSPC Pharmaceutical Group is a state-owned enterprise.

CSPC Pharmaceuticals Holdings Group Co., Ltd. is a national-level innovative enterprise integrating the research and development, production and sales of innovative drugs. The group has total assets of 41 billion yuan and 25,000 employees. The company listed in Hong Kong (01093.HK) has a market value of over HK$100 billion. It is a component stock of the Hang Seng Index and the first pharmaceutical stock in the 50 years since the Hang Seng Index was compiled. On March 22, 2019, its subsidiary company New Novo (300765.SZ) was successfully listed on the GEM. CSPC Pharmaceutical Group realized a new era of "red chip + A + New OTC Market" financing pattern.

Since its establishment, CSPC Pharmaceutical Group has continued to innovate and forge ahead with strong support from all walks of life, achieving sustained, healthy and rapid development. Currently, it has 11 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin and other provinces and cities. Its products are sold in more than 100 countries and regions around the world, with 33 varieties selling over 100 million yuan each. In 2018, the group achieved sales revenue of 30.068 billion yuan and paid various taxes of 2.76 billion yuan, making outstanding contributions to promoting the development of my country's pharmaceutical industry and regional economic construction.

Extended information:

Star product of CSPC Pharmaceutical Group

1. Enbipu Soft Capsule

Indications: Used to treat mild cases , moderate acute ischemic stroke.

2. Butylphthalide Sodium Chloride Injection

Indications: Used to improve neurological deficits in patients with acute ischemic stroke.

3. Duomeisu-doxorubicin hydrochloride liposome injection

Indications: This product can be used as a first-line systemic chemotherapy drug, or used to treat disease progression Second-line chemotherapy for AIDS-KS patients.

4. Elenon-elemene injection

Indications: used for the treatment of glioma and brain metastases; adjuvant treatment of cancerous pleural and ascites effusion.

5. Jinyouli-PEGylated recombinant human granulocyte stimulating factor injection

Indications: non-myeloid malignant tumors, can reduce febrile neutropenia incidence of infection.

6. Nolinin-Imatinib Mesylate Tablets

Indications: Treatment of chronic phase and accelerated phase of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) period or acute change period.

7. Oulaining-Oxiracetam for Injection

Indications: Used for the treatment of brain damage and the resulting neurological deficit, memory and intellectual disability.

8. Xuanning-Levoamlodipine Maleate Tablets

Indications: Hypertension, this product can be used alone or combined with other antihypertensive drugs; Chronic stable angina and variant angina can be treated with this product alone or in combination with other anti-angina drugs.

9. Oulaining-Oxiracetam Capsules

Indications: Suitable for memory and intelligence caused by mild to moderate vascular dementia, Alzheimer's dementia, and brain trauma. obstacle.

CSPC Pharmaceuticals Group-Official Website